Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure

Patients with hepatitis C virus (HCV) who have virological failure (VF) after treatment containing a nonstructural protein 5A (NS5A) inhibitor have limited retreatment options. MAGELLAN‐1 Part 2 was a randomized, open‐label, phase 3 study to evaluate the efficacy and safety of ribavirin (RBV)‐free g...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology
Main Authors: Poordad, Fred, Pol, Stanislas, Asatryan, Armen, Buti, Maria, Shaw, David, Hézode, Christophe, Felizarta, Franco, Reindollar, Robert W., Gordon, Stuart C., Pianko, Stephen, Fried, Michael W., Bernstein, David E., Gallant, Joel, Lin, Chih‐Wei, Lei, Yang, Ng, Teresa I., Krishnan, Preethi, Kopecky‐Bromberg, Sarah, Kort, Jens, Mensa, Federico J.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2018
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5901397/
https://ncbi.nlm.nih.gov/pubmed/29152781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.29671
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items